Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2B | P41595 | 4/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314525 | 1.00 | APLNR (0.35) | APLNRALDH1A1HTTGFERHTR2A | |
| SCHEMBL314523 | 1.00 | APLNR (0.35) | APLNRALDH1A1HTTGFERHTR2A | |
| SCHEMBL14327446 | 0.89 | ALDH1A1 (0.33) | ALDH1A1HTTGFERHTR2AHTR2C | |
| SCHEMBL314416 | 0.87 | — | — | |
| SCHEMBL314289 | 0.83 | CYP11B1 (0.32) | APLNRALDH1A1 | |
| SCHEMBL314290 | 0.83 | CYP11B1 (0.32) | APLNRALDH1A1 | |
| SCHEMBL314291 | 0.83 | CYP11B1 (0.32) | APLNRALDH1A1 | |
| SCHEMBL316012 | 0.79 | TNIK (0.35) | — | |
| SCHEMBL314016 | 0.76 | TNKS2 (0.38) | APLNRALDH1A1HTTGFER | |
| SCHEMBL314015 | 0.76 | TNKS2 (0.38) | APLNRALDH1A1HTTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | APLNR 2076/4885ALDH1A1 2295/4885HTT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.